Speakers

 
Eric Rhodes - Horizon Discovery
 
BIO
Eric has over 15 years of commercial experience in the gene regulation and editing field. Prior to joining Horizon Discovery as Chief Technology Officer at the start of 2012 he spent 10 years at Sangamo Biosciences and 3 years at Sigma-Aldrich involved in applications of zinc finger technology. Eric is part of the senior management team at Horizon and manages the technology development and Centres of Excellence groups.
 
 
Farren Isaacs - Yale University

BIO
Farren Isaacs is Assistant Professor of Molecular, Cellular and Developmental Biology and Systems Biology Institute at Yale University. He received a B.S.E in Bioengineering from the University of Pennsylvania and his Ph.D. from the Biomedical Engineering Department and Bioinformatics Program at Boston University. In his Ph.D., he pioneered the development of synthetic RNA components capable of probing and programming cellular function. As a research fellow in the Genetics at Harvard, he then invented enabling technologies for genome engineering, including MAGE (Multiplex Automated Genome Engineering) and CAGE (Conjugative Assembly Genome Engineering). His research is focused on developing foundational genomic and cellular engineering technologies with the goal of developing new genetic codes, and engineered cells that serve as factories for chemical, drug and biofuel production. He has recently been named a "rising young star of science" by Genome Technology Magazine and a Beckman Young Investigator by the Arnold and Mabel Beckman Foundation.
 
 
Feng Zhang - MIT & Harvard

BIO
Feng Zhang in the Keck Career Development Assistant Professor of Neuroscience and Biological Engineering at MIT and he is also a Core Member of the Broad Institute of MIT and Harvard. As a graduate student at Stanford University, Zhang worked with advisor Karl Deisseroth to invent a set of technologies, now known as optogenetics, for dissecting the functional organization of brain circuits. His lab continues to pioneer and apply disruptive technologies including optogenetics and genome engineering (TALENs and CRISPR) to understand nervous system function and disease. Zhang’s long-term goal is to develop novel therapeutic strategies for disease treatment. He obtained a bachelor’s degree from Harvard University and a PhD in chemistry and bioengineering from Stanford University. Before joining the MIT faculty he was a junior fellow of the Harvard University Society of Fellows. He is a recipient of the Perl/UNC Prize in Neuroscience, the NIH Director’s Pioneer award, and awards from the Searle Scholars Program, McKnight, Keck, and Damon Runyon foundations.
 

Franck L. Huissier - KeyGene

BIO
Graduated Cum Laude from the University of Rouen/Pasteur Institute (France) in 1998 from the lab of Pr. Camille Rippol on the effect of air pollutant on the structure and allergen content of tree and grass pollen.
From 1999-2002, Post-doctoral fellow at the University of Wageningen in the lab of Pr. Anne-Mie Emons on the early step of the symbiotic process between Rhizobium bacteria and legume root hairs.
From 2002-2005, Post-doctoral fellow at the University of Wageningen/KeyGene in the lab of Pr. Chrysta Heyting on meiotic recombination in tomato.
From 2005-2007, Post-doctoral fellow at KeyGene N.V. under the supervision of Pr. Tom Gerats and Dr. Michiel de Both on meiotic recombination in tomato and the early development of the KeyBase technology.
From 2007 until now, scientist at KeyGene N.V. working on meiotic recombination in tomato and the development of the KeyBase technology.
For 2 years PI on the development of the KeyBase technology.
 
PUBLICATIONS
 
^ The Mismatch Repair Protein MLH1 Marks a Subset of Strongly Interfering Crossovers in Tomato.
Franck GP Lhuissier, Hildo H. Offenberg, Peter E. Wittich, Norbert O.E. Vischer and Christa Heyting 
The Plant Cell 19(3):862-876. (2007)
^ A non-symbiotic root hair tip growth phenotype in NORK-mutated legumes: Implications for nodulation factor-induced signaling and formation of a multifaceted root hair pocket for bacteria.
Esseling J.J., Lhuissier F.G. and Emons A.M.
The Plant Cell 16(4):933-944.(2004) 
^ Time course of the Cell Biological Events Evoked in the Legume Root Hairs by Rhizobium Nod Factors: State of the Art.FGP
Lhuissier, NCA de Ruijter, BJ Sieberer, JJ Esseling and AMC Emons
Annals of Botany 87: 289-302. (2001) 
^ SIMS Investigation of the Distribution of K+, Na+, Mg2+ and Ca2+ Cations in Birch Pollen.
F. Lhuissier, M.C. Verdus, B. Labulle, F. Lefebvre, C. Bocquel and C. Ripoll  
Botanica Acta 110:378-387.(1997)

 
 
BIO
Giacomo holds a PhD in computational biology and protein engineering from the Pasteur Institute in Paris and a M.Sc. in Pharmaceutical Biotechnology from the University of Bologna. Before co-founding Meiogenix, Giacomo was an analyst at Kurma Biofund. Giacomo has also co-founded Key Neurosciences and raised more than €3M euros from investors and grants for his different companies. Giacomo has business training from Stanford University (Graduate School of Business) and HEC (Executive Education) in Paris.
 
 
Gregory D. Davis  - Sigma-Aldrich Corporation, USA

BIO
Greg graduated from the University of Texas, Austin with a B.S. in Chemical Engineering in 1993 and from the University of Oklahoma with a Ph.D. in Chemical Engineering in 1998.  From 1998 to 2003, Greg worked at Clontech Laboratories (Mountain View, California) developing technologies for directed protein evolution and high throughput cloning.  His technology development efforts at Sigma-Aldrich (2004-present) have focused on targeted genome editing in bacteria via RNA-guided group II introns (1), and mammalian cells and animals via zinc finger nucleases (2,3).  His recent genome editing research has focused on single-stranded donor DNA formats (4) and CRISPR/Cas-based genome editing.  

PUBLICATIONS

^ Targeted inactivation of Francisella tularensis genes by group II introns.
Rodriguez, S. A., Yu, J. J., Davis, G., Arulanandam, B. P. & Klose, K. E. 
Appl Environ Microbiol 74, 2619-2626 (2008).
^ Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome.
DeKelver, R. C. et al. 
Genome Res 20, 1133-1142 (2010).
^ Knockout rats via embryo microinjection of zinc-finger nucleases.
Geurts, A. M. et al. 
Science 325, 433 (2009).
^ High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases.
Chen, F. et al. 
Nature Methods 8(9): 753-755 (2011).
 
 
Jens Boch - Martin Luther University Halle-Wittenberg, Germany
 
BIO
My lab focuses on the molecular activity of bacterial virulence factors that are injected into eukaryotic cells to sabotage them for the benefit of the pathogen. Our special emphasis is on TAL effectors (TALEs) from plant-pathogenic Xanthomonas which employ a unique DNA-binding domain. We solved the "code" for TALE specificity and demonstrated that artificial TALEs with almost any DNA-binding specificity can be generated. This feature makes TALEs a unique tool for biotechnology. Presently, we study the molecular details of TALE-DNA interaction, employ TALEs as remote controls for gene expression in human cells, and develop TALENs for genome editing to generate pathogen-resistant crops.

PHD
1996 "Osmoregulation in Bacillus subtilis", Philipps University Marburg, Germany.
POSTDOC
1996-1997 "Temperature-dependent regulation of virulence genes in Pseudomonas syringae", Max-Planck-Insitute for Terrestrial Microbiology, Marburg, Germany.
1997-1999, "Interaction of Pseudomonas syringae and Arabidopsis", Washington University, St. Louis, USA.
GROUP LEADER
1999-present, "Type III effectors from Pseudomonas syringae and Xanthomonas", Martin Luther University Halle-Wittenberg, Germany

PUBLICATIONS

^ Computational predictions provide insights into the biology of TAL effector target sites.
Grau, J., Wolf, A., Reschke, M., Bonas, U., Posch, S., and Boch, J.
PLoS Comp. Biol. 9, e1002962. (2013)
^ TAL effector RVD specificities and efficiencies.
Streubel, J., Blücher, C., Landgraf, A., and Boch,
J. Nat. Biotechnol. 30, 593-595. (2012)
^ Transcriptional activators of human genes with programmable DNA-specificity.
PLoS ONE 6, e19509.
^ Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu. Rev.
Geißler, R., Scholze, H., Hahn, S., Streubel, J., Bonas, U., Behrens, S.-E., and Boch, J. (2011) ^ Boch, J. and Bonas, U.
Phytopathol. 48, 419-436. (2010)
^ Breaking the code of DNA binding specificity of TAL-type III effectors.
Boch, J., Scholze, H., Schornack S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A., and Bonas, U.
Science 326, 1509-1512. (2009)

 
Jerrod Schwartz - University of Washington, US

BIO
Dr. Schwartz is currently a Helen Hey Whitney Fellow with Jay Shendure in the Department of Genome Sciences at the University of Washington.
He received his Ph.D. in Bioengineering from Stanford University with Stephen Quake and his M.Sc. from the California Institute of Technology.  Dr. Schwartz is broadly interested in developing and applying new technologies for synthetic biology, high throughput sequencing, and single molecule biophysics.  He recently developed a high-throughput method for the retrieval of accurate synthetic DNA constructs for gene and genome synthesis, and he pioneered a novel approach to integrate optical sequencing into an existing massively parallel sequencing platform.

PUBLICATIONS

^ Accurate gene synthesis with tag-directed retrieval of sequence-verified DNA molecules
Schwartz JJ, Lee C, Shendure J. 
Nature Methods 9, 913-915 (2012).
^ Capturing native long-range contiguity by in situ library construction and optical sequencing Schwartz JJ, Lee C, Hiatt JB, Adey A, Shendure J. 
Proc. Natl. Acad.
Sci. USA published ahead of print October 29 2012.
^ Colloidal lenses enable high temperature single molecule imaging and improve fluorophore photostability
Schwartz JJ, Stavrakis S, Quake SR. 
Nature Nanotechnology 5, 127-132 (2010).
^ Single molecule measurement of the "speed limit" of DNA polymerase
Schwartz JJ, Quake SR. 
Proc. Natl. Acad. Sci. USA 106, (48), 20294-20299 (2009).

 
Jingdong Tian - Duke University, Tianjin Institute of Industrial Biotechnology & Chinese Academy of Sciences
 
BIO
Jingdong Tian received his PhD in Biochemistry, Cell and Developmental Biology from Stony Brook University, NY, USA. He was a Life Sciences Research Foundation postdoctoral fellow in the Departments of Cell Biology and Genetics at Harvard Medical School before he became an Assistant Professor in the Department of Biomedical Engineering and the Institute for Genome Sciences and Policy at Duke University. Dr. Tian is now professor and director of the synthetic genomics laboratory at Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, and an adjunct professor at Duke University. His research currently focuses on developing technologies to enable effective design, construction and optimization of synthetic biological systems. He was a recipient of the Beckman Young Investigator Award and the Hartwell Individual Biomedical Research Award.
 
PUBLICATIONS

^ DNA synthesis, assembly and applications in synthetic biology.
Ma, S., Tang, N. and Tian, J. (2012)
Curr Opin Chem Biol, 16, 260-267.
^ Error correction of microchip synthesized genes using Surveyor nuclease.
Saaem, I., Ma, S., Quan, J. and Tian, J. (2012) 
Nucleic Acids Research, 40, e23.
^ Error correction in gene synthesis technology.
Ma, S., Saaem, I. and Tian, J. (2012) 
Trends Biotechnol, 30, 147-154.
^ Parallel on-chip gene synthesis and application to optimization of protein expression.
Quan J, Saaem I, Tang N, Ma S, Negre N, Gong H, White KP & Tian J. (2011) 
Nature Biotechnology 29(5), 449-52.
^ Circular polymerase extension cloning for high-throughput cloning of complex and combinatorial DNA libraries.
Quan J and Tian J. (2011) 
Nature Protocols 6, 242-251.

Jin-Soo Kim - National Creative Research Initiatives Center for Genome Engineering & Seoul National University

BIO
Jin-Soo Kim is an entrepreneur and a chemist-turned-biologist. He graduated from Seoul National University in 1987 with a major in chemistry. He earned a master degree in chemistry from Seoul National University in 1989 and a Ph. D. in biochemistry from University of Wisconsin-Madison in 1994. After postdoctoral training at Howard Hughes Medical Institute/Massachusetts Institute of Technology, he came back to Seoul in 1997 to serve as a Principal Investigator at Samsung Biomedical Research Institute. He co-founded a biotechnology company, ToolGen, Inc., focused on zinc finger technology in 1999, and served as CEO and CSO for the subsequent 6 years. He joined the faculty of Department of Chemistry at Seoul National University in 2005. He has published over 50 articles and filed 20 patent applications mostly in the field of gene regulation and genome editing.

PUBLICATIONS

^ A library of TAL effector nucleases spanning the human genome.
Kim YS et al. and Kim JS (2013)
Nature Biotechnol. 31, 251.
^ Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease.
Cho SW et al. and Kim JS (2013)
Nature Biotechnol. 31, 230. (Featured in News and Views, Nature 495, 50; Nat. Biotechnol. 31, 208; Nat. Methods 10, 189; and SciBX 6, 1)
^ Knockout mice created by TALEN-mediated gene targeting.
Sung YH, et al. and Kim JS*, Lee HW* (2013)
Nature Biotechnol. 31, 23. (* co-corresponding authors)

^ Precision genome engineering with programmable DNA-nicking enzymes.
Kim E et al. and Kim JS (2012)
Genome Res. 22, 1327.
Featured in Research Highlights, Nat. Methods 9, 536 and Nat. Rev. Genet. 13, 378
^ Surrogate reporters for enrichment of cells with nuclease-induced mutations.
Kim H et al. and Kim JS (2011)

 
 
J. Keith Joung - Massachusetts General Hospital (MGH) & Harvard Medical School

BIO
Dr. J. Keith Joung is Associate Chief of Pathology for Research at Massachusetts General Hospital (MGH) and Associate Professor of Pathology at Harvard Medical School.  He received his M.D. and Ph.D. degrees from Harvard Medical School and did post-doctoral research with Carl Pabo at the Massachusetts Institute of Technology.  Dr. Joung’s research interests are in the development and application of engineered DNA-binding domains and customized nucleases.  Over the past five years, his lab has pioneered methods for targeted genome editing using engineered zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas RNA guided nucleases (RGNs).  Dr. Joung is the recipient of a NIH Director’s Pioneer Award, a NIH Transformative R01 award, and the Jim and Ann Orr MGH Research Scholar award. 

PUBLICATIONS

^ Synergistic regulation of human gene expression using TALE activators.
Maeder ML, Linder SJ, Reyon D, Angstman JF, Fu Y, Sander JD, Joung JK. Robust,
Nat Methods. 2013 Mar;10(3):243-5.  
^ Efficient genome editing in zebrafish using a CRISPR-Cas system.
Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK.
Nat Biotechnol. 2013 Mar;31(3):227-9.
^ FLASH assembly of TALENs for high-throughput genome editing.
Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK.
Nat Biotechnol. 2012 May;30(5):460-5.
TALENs: a widely applicable technology for targeted genome editing.
Joung JK, Sander JD.
Nat Rev Mol Cell Biol. 2013 Jan;14(1):49-55. Review.
^ Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA).
Sander JD, Dahlborg EJ, Goodwin MJ, Cade L, Zhang F, Cifuentes D, Curtin SJ, Blackburn JS, Thibodeau-Beganny S, Qi Y, Pierick CJ, Hoffman E, Maeder ML, Khayter C, Reyon D, Dobbs D, Langenau DM, Stupar RM, Giraldez AJ, Voytas DF, Peterson RT, Yeh JR, Joung JK.
Nat Methods. 2011 Jan;8(1):67-9.
 
John Glass - JCVI

BIO 
Dr. John Glass is a Professor and Group Leader of the JCVI Synthetic Biology & Bioenergy Group, where also leads the Mycoplasma Biology team. His expertise is in molecular and synthetic biology, virology, mycoplasmology and microbial genomics. At the JCVI has been one of the leaders of the synthetic cell program that produced the world’s first synthetic bacterial cell in 2010, he led the synthetic influenza virus vaccine program, and is one of the leaders of the JCVI minimal bacterial cell program.
Prior to joining the JCVI Dr. Glass spent five years in the Infectious Diseases Research Division of the pharmaceutical company Eli Lilly where he directed a Hepatitis C virology group and a microbial genomics group (1998-2003).
Glass earned his undergraduate (biology) and graduate degrees from the University of North Carolina at Chapel Hill. His Ph.D. work was on RNA virus genetics in the laboratory of Gail Wertz. He was on the faculty and did postdoctoral fellowships in the Microbiology Department of the University of Alabama at Birmingham in polio virology and mycoplasma pathogenesis (1990-1998). On sabbatical leave in Ellson Chen's lab at Applied Biosystems Inc.(1995-1997) he sequenced the genome of Ureaplasma parvum and began his study mycoplasma genomics. 
Glass has been an adjunct faculty member in the Molecular and Cellular Biology curriculum at the University of Maryland at College Park since 2009. He is currently on the Scientific Advisory Board of the Global Viral Network. Glass was Chairman of the Mycoplasmology Division of the American Society for Microbiology from 2012 to 2013.
 
Kevin Munnelly - CEO Gen9 Inc.
 
BIO
Kevin Munnelly has over 20 years experience with molecular biology, chemistry, software, instrument development, and statistical analysis. Prior to Gen9, he was a Leader and General Manager in the Next Generation qPCR business at Life Technologies where he was responsible for a multimillion dollar business segment as well as development of custom genomics solutions through collaborations with end user scientists. Prior to Life Technologies, Mr. Munnelly was Vice President and General Manager of BioTrove Inc, which was acquired by Life Technologies in 2009. At BioTrove, he led the research, development, manufacturing and commercial organizations. Prior to BioTrove, Mr. Munnelly was a Senior Manager of the Platform Technology group at Millennium Pharmaceuticals which developed new technologies for drug discovery, development, personalized medicine and biotherapeutics manufacturing. Earlier in his career, he had many different scientific roles in drug discovery, assay development, statistical analysis and platform development. He holds an A.B. with honors from Bowdoin College in Biochemistry and Molecular Biology and an MBA in Entrepreneurship, Magna Cum Laude, from Babson College.


Piet Herdewijn - KU Leuven

BIO
Piet Herdewijn holds a PhD (1981) and a Habilitation (1990) from KU Leuven. He was a fellow of FWO and of the von Humboldt Foundation and did a postdoctoral study at the University of Konstanz, Germany. He was associated at the University of Ghent (1990-2002) and at the University of Evry-Val-d’Essone, Paris, France (2011-…). He is a full professor at KU Leuven since 1993. He is a member of the Royal Academy of Medicine, he holds a Francqui Chair at the University of Ghent (2008), he is member of the directory board of the Rega Institute, and was recently awarded an ERC advanced grant. He is (co)founder and first president of the International Society of Nuclosides, Nucleotides and Nucleic Acids (IS3NA). His main interest is bioorganic chemistry and more particular nucleoside and nucleic acids chemistry. In this field of research he has published 600 articles in international peer reviewed journals.

PUBLICATIONS

^ Cyclohexene nucleic acids (CeNA): serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA.
J. Wang, B. Verbeure, I. Luyten, E. Lescrinier, M. Froeyen, C. Hendrix, H. Rosemeyer, F. Seela, A. Van Aerschot and P. Herdewijn
J.Am.Chem.Soc. 2000, 122, 8595-8602.
^ Enzymatic synthesis of phosphonomethyl oligonucleotides by therminator polymerase.
M. Renders, G. Emmerechts, J. Rozenski, M. Krecmerová, A. Holý, P. Herdewijn
Angewandte Chem. Int. Ed. 2007, 46, 2501-2504.
^ Amino Acid Phosphoramidate Nucleotides as Alternative Substrates for HIV-1 Reverse Trancriptase.
O. Adelfinskaya, P. Herdewijn
Angewandte Chem. Int. Ed. 2007, 46, 4365-4368.
^ Chemical evolution of a bacterium’s genome.
P. Marlière, J. Patronix, V. Döring, P. Herdewijn, M. Bouzon, R. Mutzel
Angew. Chem., 2011, 50, 7109 –7114.
^ Synthetic genetic polymers capable of heredity and evolution.
V.B. Pinheiro, A.I. Taylor, C. Cozens, M. Abramov, M. Renders, S. Zhang, J.C. Chaput, J. Wengel, S.Y. Peak-Chew, S.H.P. McLaughlin, P. Herdewijn, P. Holliger
Science, 2012, 336, 341-344.
 

Philippe Duchateau - Cellectis

BIO
Philippe Duchateau, PhD received his doctorate in biochemistry and molecular biology from the University of Lille and the Institut Pasteur. He joined Cellectis in 2001 after nine years at the Cardiovascular Research Institute of the University of California, San Francisco (USA). He previously headed Cellectis’ Research department, starting in 2004.